Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma
Ailin Lepletier(Griffith University), Mark J. Smyth(Peter MacCallum Cancer Centre), Michele W.L. Teng(The University of Queensland), Mario Mandalà(University of Perugia), Melissa Eastgate(The University of Queensland), Daniela Massi(University of Florence), Alexander M. Menzies(The University of Sydney), Tobias Bald(QIMR Berghofer Medical Research Institute), Anna Kuchel(The University of Queensland), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Jason Madore(QIMR Berghofer Medical Research Institute), Barbara Merelli(Ospedale Papa Giovanni XXIII), Elizabeth Ahern(Monash Health), William C. Dougall(Queensland University of Technology), Domenico Mallardo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Jake S. O’Donnell(The University of Queensland), Elizabeth S. McDonald(QIMR Berghofer Medical Research Institute), Sally‐Ann Pearson(QIMR Berghofer Medical Research Institute), Georgina V. Long(The University of Sydney), Bertrand Routy(Centre Hospitalier de l’Université de Montréal), Xian-Yang Li(QIMR Berghofer Medical Research Institute), Rebecca L. Johnston(QIMR Berghofer Medical Research Institute), Richard A. Scolyer(The University of Sydney), Charles Leduc(United Arab Emirates University), James S. Wilmott(The University of Sydney), J. C. A. Stagg(QIMR Berghofer Medical Research Institute), Nicola Waddell(QIMR Berghofer Medical Research Institute)
Cited by 113
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k